Grants & Awards Programs

• Million Dollar Bike Ride 2024 Pilot Grant

  The 2024 MDBR Grant Program is now accepting Letters of Interest which are due no later than Friday, September 20, 2024 by 8pm (EST). The 2024 grant for Complex Lymphatic Anomalies projects is $62,398. Complete information can be found on the Orphan Disease Center website. The research area for Complex Lymphatic Anomalies is as follows:

  Complex Lymphatic Anomalies (CLA): We are soliciting research applications for one $62,398 award focused on Complex Lymphatic Anomalies (CLAs), including Gorham-Stout disease (GSD), generalized lymphatic anomaly (GLA), kaposiform lymphangiomatosis (KLA) and central conducting lymphatic anomaly (CCLA). Priority will be given to laboratory or clinical research proposals with a strong likelihood of future federal funding. Areas of interest include, but are not limited to, genomic and/or proteomic analyses, biomarker identification/validation, cell line creation and characterization, and imaging. This award is made possible by Team LGDA (Lymphangiomatosis & Gorham’s Disease Alliance), Team LGD Alliance Europe and Team LMI (Lymphatic Malformation Institute).

  The ODC is offering 42 research opportunities focusing on 34 different rare diseases. This program provides a one-year grant to support research related to a rare disease represented in the 2024 Million Dollar Bike Ride. Number of awards and dollar amounts vary per disease based on fundraising totals by each disease team.

  The MDBR 2024 Pilot Grants are open to the international community holding a faculty‐level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation. Prior MDBR award recipients must have current and updated project reporting to be eligible for selection.

  For more information or to submit an LOI, click here.

  Learn More >
• AVF Research Grants

  Applications for AVF Research Grants are OPEN!

  Available grants:

  - 2025 AVF Basic Science Research Grant:  Provides a 1 year, $15,000 grant for an original research project in venous disease

  - 2025 AVF-JOBST Clinical Research Grant:  Provides a $85,000 grant over two years for original, clinical research in venous diseases, lymphatic diseases, or lipedema

  - 2025 AVF-BSCI Translational Research Grant:  Provides a $85,000 grant over two years for an original, translational research project in venous disease

  Submission Deadline: September 1, 2024

  Learn More >
• LIGHT:  Lymphatic Imaging, Genomics, and Phenotyping Technologies

  The Lymphatic Imaging, Genomics, and pHenotyping Technologies (LIGHT) program seeks comprehensive diagnostic solutions across three technical areas: diagnosis and monitoring through biomarker discovery; imaging technologies; and prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction. If successful, LIGHT will not only illuminate the unseen aspects of the lymphatic system through novel diagnostic approaches, but also significantly improve patient care and outcomes by gaining a deeper understanding of its critical role in health.

  ARPA-H is always seeking unconventional approaches and innovative solutions to pressing health challenges. LIGHT targets an overlooked system in order to catalyze transformative advances in lymphatic medicine.

  Learn More >
• Rare Diseases Clinical Research Consortia for the Rare Diseases Clinical Research Network

  Funding Opportunity Title:  Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) (PAR-24-206)

  The objective of this Notice of Funding Opportunity (NOFO) is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research. Special emphasis will be placed on the early and timely identification of individuals with rare diseases and clinical trial readiness.

  Key Dates

  Posted Date:  April 02, 2024
  Open Date (Earliest Submission Date):  July 12, 2024
  Letter of Intent Due Date(s):  30 days prior to the application due date

  

  Expiration Date:  August 14, 2024
  Due Dates for E.O. 12372:  Not Applicable

  Learn More >
• Patient-Centered Outcomes Research Institute

  The Patient-Centered Outcomes Research Institute (PCORI) is an independent, nonprofit research organization that seeks to empower patients and others with actionable information about their health and healthcare choices. We fund comparative clinical effectiveness research (CER), which compares two or more medical treatments, services, or health practices to help patients and other stakeholders make better informed decisions.

  On Jan. 9, 2024, PCORI will begin accepting Letters of Intent for PCORI Funding Announcements (PFAs). Register for an Applicant Town Hall today to learn more about upcoming PFAs.

  PCORnet® is intended to improve the nation’s capacity to efficiently conduct patient-centered health research, particularly CER, by providing a large, highly representative network of health data, research expertise and patient insights. Read the latest post to learn more about the advantages of using PCORnet for your research, including four new tools aimed at enabling you to maximize every aspect of your research.

  Learn More >
• Notice of Special Interest (NOSI): Lymphatic System in Health and Disease (R01)

  This notice (#NOT-HL-23-099) was issued by National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), and National Center for Complementary and Integrative Health (NCCIH).

  This NOSI aims to promote research on the normal biology of the lymphatic system (LS) and ascertain factors that account for individual differences in the LS impacting resilience. Also of interest is research to identify factors that account for individual differences in pathobiology and response to treatments, and understand the mechanisms and potential novel therapeutics for lymphatic diseases (LDs) and secondary heart, lung, blood, and sleep (HLBS) disorders related to lymphatic dysfunction. Further, this notice intends to stimulate lymphatic research at molecular, cellular, tissue, organ, and whole-body levels, and aims to facilitate research on innovations for identifying and intervening in LDs across the lifespan and disease states. The NOSI may also reach a broader community and facilitate multidisciplinary research needed to determine the function and role LS in health, disease prevention, and to identify biomarkers and test prevention and treatment strategies with specific attention to social determinants of health, and both treatment and health inequities.

  This notice applies to due dates on or after October 5, 2023, and subsequent receipt dates through September 7, 2026. This NOSI expires on September 8, 2026; thus no applications will be accepted on or after September 8, 2026.

  For more information, click here.

  Learn More >
• 
  Congressionally Directed Medical Research Programs (CDMRP)

  The CDMRP originated in 1992 via a Congressional appropriation to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders-the American public, the military, and Congress.

  Hallmarks of the CDMRP include:
  - investing in groundbreaking research
  - targeting critical gaps
  - reviewing application using a two-tier formal review with no standing peer review panels and no “pay line”
  - involving consumer advocates throughout the program cycle
  - supporting both the next generation of researchers and established scientists.
  - funding the full pipeline of research development, including basic, translational, and clinical research.
  - fostering (or employing) collaboration and synergy

  The CDMRP fills research gaps by funding high impact, high risk and high gain projects that other agencies may not venture to fund. While individual programs are unique in their focus, all of the programs managed by the CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. The CDMRP strives to transform health care for Service Members and the American public through innovative and impactful research.

  Congressionally Directed Medical Research Programs (health.mil)

  Peer Reviewed Medical Research Program, FY23 Topic Areas; Congressionally Directed Medical Research Programs (health.mil)

  PRMRP Glitz Sheet_7Feb23.pdf (health.mil)

  HT9425-23-PRMRP-IIRA-GG.pdf (health.mil)

• 
  Lymphatic researchers needed for NIH Study Sections

  LE&RN was asked to recruit and has registered through the CSR portal in order to recommend potential reviewers. They have identified the following three Study Sections that review lymphatic grant proposals:

  * Hypertension and Microcirculation (HM) Study Section reviews applications dealing with propulsion of lymph, lymphatic tone, and pathogenesis of lymphedema with more focus on functional studies; sometimes reviews applications about the lymphatic system in infection and inflammation depending on the outcome of research, namely whether focused on lymphatics or infection.
  
  
  * Immunity and Host Defense (IHD) and Innate Immunity and Inflammation (III) Study Sections may review applications that address lymphatic role in infection.
  
  
  * Cardiovascular Differentiation and Development (CDD) Study Section reviews applications involving lymphatic development, lymphangiogenesis, and lymphedema focusing on structure.

  If you are willing to serve on one or more of the above-identified NIH Study Sections, please contact LE&RN at LERN@LymphaticNetwork.org with the following information:

  * Name
  * Affiliation
  * Study Section(s) on which you are willing to serve
  * In 50 words or less, your qualifications for each Study Section selected
  * Include CV

  Investigators will not be able to review their own research or research on which they are collaborators. However, this will not prevent your research from being reviewed by the Study Section. Per NIH: If a researcher is on a Study Section and has an application, his or her application is reviewed by a special emphasis panel. This is a common practice that happens all the time. This should not be an obstacle to joining a Study Section.